GenSci145 as Monotherapy or in Combination Therapy, in Participants With PIK3CA-mutated, Locally Advanced or Metastatic Solid Tumors.

NCT07407504 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

186

Enrollment

INDUSTRY

Sponsor class

Conditions

Locally Advanced or Metastatic Solid Tumors With PIK3CA-mutated

Interventions

DRUG: GenSci145 tablets

Sponsor

Changchun GeneScience Pharmaceutical Co., Ltd.